Literature DB >> 23093298

[Accidental levomethadone intoxication in a palliative patient].

B Michel-Lauter1, C Maier, A Schwarzer.   

Abstract

Levomethadone is a strong opioid which is used rarely in the treatment of special pain syndromes in Germany. A main field for the usage of Levomethadone, which has be applied as a oral fluid, is the opioid replacement therapy of heroin-addicts. Due to the long plasma half life and its high inter-individual variability, the application implies a risk of cumulation leading to an overdosage. It is not recommended to use a fixed equianalgesic formula for the dosage conversion from other opioids. The conversion starts with a low start dose, an individual titration follows. In this case-report, the difficulty of cumulation, inaccurate drug dispensary and the characteristic of dosage calculation of levomethadone is discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23093298     DOI: 10.1007/s00482-012-1229-2

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  10 in total

Review 1.  Pharmacokinetics of methadone.

Authors:  Ralph A Lugo; Kristin L Satterfield; Steven E Kern
Journal:  J Pain Palliat Care Pharmacother       Date:  2005

2.  Increased risk of suicide under intrathecal ziconotide treatment? - a warning.

Authors:  Christoph Maier; Hans-Helmut Gockel; Kai Gruhn; Elena K Krumova; Marc-Andreas Edel
Journal:  Pain       Date:  2010-10-30       Impact factor: 6.961

Review 3.  A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project.

Authors:  S King; K Forbes; G W Hanks; C J Ferro; E J Chambers
Journal:  Palliat Med       Date:  2011-07       Impact factor: 4.762

4.  Practicability, safety, and efficacy of a "German model" for opioid conversion to oral levo-methadone.

Authors:  Christoph Ostgathe; Raymond Voltz; Annika Van Aaaken; Carsten Klein; Rainer Sabatowski; Friedemann Nauck; Jan Gaertner
Journal:  Support Care Cancer       Date:  2011-12-01       Impact factor: 3.603

Review 5.  Methadone: applied pharmacology and use as adjunctive treatment in chronic pain.

Authors:  R Brown; C Kraus; M Fleming; S Reddy
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

6.  Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval.

Authors:  Nicolas Ansermot; Ozgür Albayrak; Jürg Schläpfer; Séverine Crettol; Marina Croquette-Krokar; Michel Bourquin; Jean-Jacques Déglon; Mohamed Faouzi; Norbert Scherbaum; Chin B Eap
Journal:  Arch Intern Med       Date:  2010-03-22

7.  Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial.

Authors:  John S Morley; John Bridson; Tim P Nash; John B Miles; Sarah White; Matthew K Makin
Journal:  Palliat Med       Date:  2003-10       Impact factor: 4.762

8.  [Neurological complications and loss of efficacy with intrathecal pain therapy].

Authors:  D Kindler; C Maier; T Kagel; S Schulz; T Weiss; M Zenz
Journal:  Schmerz       Date:  2005-04       Impact factor: 1.107

Review 9.  [Osteoporosis pain management].

Authors:  Gerhard Dinges
Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther       Date:  2009-09-11       Impact factor: 0.698

10.  Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?

Authors:  C Ripamonti; L Groff; C Brunelli; D Polastri; A Stavrakis; F De Conno
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

  10 in total
  2 in total

1.  [Dependency syndrome and hyperalgesia due to an opioid therapy for curative treatable pain. Case report of an apparent palliative patient].

Authors:  B Michel-Lauter; K Bernardy; A Schwarzer; V Nicolas; C Maier
Journal:  Schmerz       Date:  2013-09       Impact factor: 1.107

Review 2.  [Differential indications of opioids in pain therapy].

Authors:  J Heyn; S C Azad
Journal:  Anaesthesist       Date:  2017-11       Impact factor: 1.041

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.